Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.
Overview
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease is a phase 3 interventional study registered as NCT00434148 by Novartis Pharmaceuticals, with 162 participants recorded, started 2006-12 and reaching its primary completion in 2010-03. Interventions recorded: Pasireotide. Conditions recorded: Cushing's Disease.
Linked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Shares Pasireotide, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Shares Pasireotide, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialMulticenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStudy of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialStrict IGF-1 Control in Acromegaly
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialCabergoline in Nonfunctioning Pituitary Adenomas
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Potency of a High Cabergoline Dosage in Microprolactinomas
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialA Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.